Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964346 | 0.88 | ADRB2 (0.53) | KMT2AMEN1MAPTMAPK1GAA | |
| SCHEMBL5964034 | 0.80 | ADRB2 (0.43) | KMT2AMEN1MAPTMAPK1GAA | |
| SCHEMBL5964591 | 0.80 | MEN1 (0.48) | KMT2AMEN1MAPK1GAA | |
| SCHEMBL5964497 | 0.79 | MEN1 (0.47) | KMT2AMEN1MAPTMAPK1GAA | |
| SCHEMBL5964271 | 0.78 | ADRB3 (0.53) | GAAADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL5963803 | 0.78 | FAAH (0.45) | ADRB2ADRB1ADRB3KCNH2 | |
| SCHEMBL5964374 | 0.77 | ADRB1 (0.49) | ADRB2ADRB1ADRB3SLC6A3 | |
| SCHEMBL5963963 | 0.76 | ADRB1 (0.57) | KMT2AMEN1MAPTMAPK1GAA | |
| SCHEMBL5964298 | 0.72 | ADRB3 (0.59) | KMT2AMEN1ADRB2ADRB1ADRB3 | |
| SCHEMBL2024942 | 0.72 | ADRB3 (0.76) | ADRB2ADRB1ADRB3KCNH2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | KMT2A 2160/4885MEN1 4443/4885MAPT 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.